Takeda's Qdenga (TAK-003) is approved in many countries with 4.5 years of Phase III data showing 84.1% protection against hospitalisation, a genuine scientific milestone. But 61.2% efficacy means roughly 39 of every 100 vaccinated people exposed to dengue still get the disease, and Dengvaxia has left the market. Why the clinical data itself argues for layered protection, vaccine plus physical prevention.
For most of the 20th century, dengue had no vaccine. The virus's four serotypes, its complex immune interactions, and the risk of antibody-dependent enhancement, a phenomenon where prior exposure to one serotype can actually worsen a second infection, made developing a safe, effective dengue vaccine one of the hardest problems in infectious disease science.
That problem has now been substantially solved. Takeda Pharmaceuticals' dengue vaccine, Qdenga (TAK-003), has been approved in many countries and prequalified by the WHO, and the landmark TIDES trial has reported about 4.5 years of Phase III follow-up showing sustained protection. This is a genuine scientific milestone, something to celebrate without qualification.
And yet the numbers contain a gap that matters enormously for how we think about dengue protection.
What Qdenga Actually Delivers
The TIDES trial is one of the most comprehensive vaccine efficacy studies in recent memory. More than 20,000 participants across eight countries, randomised two-to-one between vaccine and placebo, and followed for about 4.5 years (Tricou et al., 2024). The results confirm:
- 61.2% efficacy against virologically confirmed dengue at 4.5 years post-vaccination (Tricou et al., 2024)
- 84.1% protection against dengue hospitalisation (Tricou et al., 2024)
- Efficacy against all four serotypes in participants with prior dengue exposure, and against DENV-1 and DENV-2 in seronegative participants (Tricou et al., 2024)
The hospitalisation figure is particularly important. Dengue kills through its severe presentations, haemorrhagic fever, dengue shock syndrome, rather than through the typical self-limiting febrile illness that most infected people experience. A vaccine that prevents most hospitalisations is protecting people from the cases that matter most clinically.
Qdenga is approved in many countries and holds WHO prequalification. For endemic regions, for travellers, and increasingly for residents of Europe's Mediterranean coast where dengue transmission is occurring locally, it represents a real, evidence-based option.
The Number Nobody Mentions: 38.8%
Vaccine efficacy of 61.2% means that, in a population of 100 fully vaccinated people exposed to dengue, approximately 39 will still get the disease.
This is not a failure of the vaccine, 61% efficacy against a four-serotype virus with complex immune dynamics is a genuinely difficult target to hit, and Qdenga hits it reliably. But it is a number that has real-world implications for how dengue prevention should be structured.
The WHO's own dengue fact sheet says one vaccine, Qdenga, is available and licensed in some countries, and that it is recommended only for those aged 6 to 16 years in high transmission settings. WHO stresses that prevention and control rely on vector control, with early detection and access to proper medical care. The vaccine reduces the probability of infection. It does not eliminate exposure.
For a traveller spending two weeks in Thailand, a 61% reduction in dengue risk is substantial. For a child growing up in a dengue-endemic neighbourhood, experiencing multiple exposure events per year across a decade of childhood, the residual 39% risk over a lifetime of exposure becomes significant. Layered protection, vaccine plus physical prevention, is not just cautious thinking; it is what the clinical data recommends.
The Dengvaxia Exit Changes the Landscape
In parallel with Qdenga's success, Sanofi has permanently discontinued its dengue vaccine Dengvaxia for commercial reasons; the European Commission withdrew its EU marketing authorisation on 21 October 2025.
Dengvaxia's commercial failure has a specific cause. The vaccine was rolled out in a Philippine school programme before a 2018 reanalysis of the trial data found a troubling pattern: in people who had never previously been infected with dengue (seronegative), the vaccine was associated with a higher risk of hospitalisation for dengue on later natural infection. The finding reshaped how regulators approached dengue vaccines, and the vaccine's reputation never recovered.
The Dengvaxia episode had a chilling effect on dengue vaccine development broadly and made regulatory agencies significantly more cautious about approval pathways. It is one of the reasons Qdenga's TIDES trial was so large and so long: the field needed to demonstrate unambiguous safety in seronegative individuals before a successor product could achieve broad uptake. Qdenga has cleared that bar.
The withdrawal of Dengvaxia leaves Qdenga as the main WHO-prequalified dengue vaccine in active distribution.
Vaccine market concentration is not inherently problematic, but it underlines the importance of not treating any single tool as sufficient.
What About Europe Specifically?
European dengue risk sits at an interesting intersection of vaccination access and transmission dynamics.
Qdenga is authorised in the EU for prevention of dengue disease from 4 years of age, but WHO recommends it only for those aged 6 to 16 years in high transmission settings.
At the same time, locally acquired dengue is now an annual reality in parts of southern France, Spain, and Italy. In 2024, the EU/EEA recorded 304 autochthonous dengue cases, up from 71 in 2022. As Aedes albopictus spreads to previously unaffected areas, the catchment area for locally acquired cases is growing.
For Europeans, the practical calculus is straightforward:
- If you are travelling to a dengue-endemic region, talk to a travel medicine specialist about Qdenga, it is the most effective option available and 4.5 years of safety data are reassuring.
- If you live in or are visiting Mediterranean Europe during the warm months when the mosquito is active, vaccination access may be limited and the vaccine would not typically be recommended for short-term exposure anyway, in which case personal protection measures are your primary tool.
- In either scenario, the 39% of vaccine-protected individuals who remain susceptible, and the much larger proportion who are not vaccinated at all, need a second layer of protection.
Layered Defence: The Standard the Data Supports
The phrase "layered protection" gets used freely in public health communications, but it deserves unpacking. It does not mean using multiple imperfect tools to feel busy. It means recognising that different protective mechanisms operate through different pathways, and combining them produces a combined efficacy that no single tool achieves.
A vaccinated individual who also uses physical barriers, screens, nets, appropriate clothing during peak biting hours, reduces their exposure probability at two independent points: they are less likely to become infected if bitten (vaccine efficacy), and they are less likely to be bitten at all (physical protection). The mathematical combination of these effects, even when each individual element is imperfect, produces substantially better overall protection.
Qdenga is a landmark achievement. Dengue vaccine science has arrived. But the science also says that 39 out of 100 vaccinated people are not protected, that the vaccine market now has only one global player, and that transmission seasons in Europe are getting longer and geographically wider.
The answer to all three of those data points is the same: don't put everything on one tool.
Sources: TIDES 4.5-year results (Tricou et al., 2024) | WHO Dengue vaccine prequalification | WHO Dengue fact sheet | EMA Qdenga | EMA Dengvaxia | ECDC autochthonous dengue
Published 2026-05-05 · Mosticare Editorial
This article is general information, not medical advice. Ask a doctor or pharmacist about your own health.